CClinicalTrials.gg
TerminatedNCT03195920Updated Apr 17, 2024

Feasibility Study of an Enhanced Lithotripsy System in the Treatment of Urinary Stone Disease

An interventional study of Enhanced Lithotripsy System in Urinary Stone, sponsored by Avvio Medical. Terminated at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-17.

Sponsored by Avvio Medical · Not applicable, Interventional, and Device feasibility

Why this study was terminated
Interim data was sufficient for study purpose
Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a single arm, single center study to assess the safety and efficacy of a form of extracorporeal lithotripsy, called the Enhanced Lithotripsy System, to treat urinary stones.

Read the detailed description

This is a single arm, single center study to assess the safety and efficacy of a form of extracorporeal lithotripsy, called the Enhanced Lithotripsy System, to treat urinary stones. Subjects will be treated up to 2 times with the Enhanced Lithotripsy System and followed for 30 days after the last treatment session.

02

Conditions studied

  • Urinary Stone
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Individuals presenting with one urinary stone-apparent on a computed tomography scan within the last 14 days
  • Males and females aged 18 or older
  • Capable of giving informed consent, and willing to have the informed consent process videotaped
  • Stone size, as estimated by pre-operative computed tomography, with all dimensions 15 mm or less.

Exclusion criteria

Exclusion Criteria:

  • Individuals under 18 years of age
  • Individuals with radiolucent stones
  • Individuals with stones in the lower pole of kidney
  • Individuals not following up in the treating hospital
  • Individuals with history of cystinuria
  • Individuals with urine pH below 5.5
  • Individuals with untreated urinary tract infection
  • Individuals who are not willing to use adequate method of contraception during the study period
  • Women who are pregnant, lactating or planning pregnancy during the study period
  • Individuals with a coagulation abnormality or taking prescription anticoagulants.
  • Individuals with mobility issues who are unable to comfortably lie still for up to 30 minutes or roll from their back to their side
  • Individuals belonging to a vulnerable group (pregnant, mentally disabled, physically disabled, prisoner, etc.)
  • Individuals with a body mass index greater than 35
  • Individuals with ASA score of 3 or greater general anesthesia risk level
  • Known sensitivity to possible medications used before, during, or after the treatment procedure, including but not limited to the following: sedative agents, general anesthetics, topical anesthetics, and opioid analgesics
04

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Enhanced Lithotripsy System

    Treatment for urinary stones with the Enhanced Lithotripsy System

    Device: Enhanced Lithotripsy System

Interventions

  • DeviceEnhanced Lithotripsy System

    The Enhanced Lithotripsy System is a type of lithotripsy system comprising a console, treatment head, and Acoustic Energy Focusing material. Operation of the Enhanced Lithotripsy System entails combined action of extracorporeal insonation and Acoustic Energy Focusing material to fragment urinary stones.

05

What researchers measure

Primary outcomes

  1. Proportion of subjects with serious device-related adverse events (safety)

    Safety: Proportion of subjects with serious device-related adverse events

    Time frame: 30 days after last treatment session

Secondary outcomes

  1. Successful treatment of urinary stone

    Proportion of subjects with successful treatment or urinary stone

    Time frame: 14 days after last treatment session

Other outcomes

  1. Change in pain score

    Pelvic Pain of the Patient (Min - Zero, Max - 10), Higher score means more pain

    Time frame: Baseline and Post Procedure Days 1, 2, 3, 7, 14, and 30

  2. Time to passage of stones

    Post-Treatment time to passage of stone fragments after treatment

    Time frame: 30 days after last treatment session

  3. Pain medication usage

    Use and quantity of pain medication

    Time frame: Baseline and Days 1, 2, 3, 7, 14, and 30

06

Study locations

1 site
  • Muljibhai Patel Urological Hospital
    Nadiad, Gujarat 387 001, India
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03195920
Lead sponsor
Avvio Medical
Responsible party
Sponsor
First posted
Jun 22, 2017
Start date
Jul 22, 2017
Primary completion
Jun 25, 2018
Completion
Oct 5, 2022
Last update
Apr 17, 2024

Study contacts

Mahesh Desai, MS, FRCS
principal investigator · Muljibhai Patel Urological Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion